FDA's GLP-1 Compounding Policy: Rules & Shortage Resolution

Last Updated: MARCH 2026

The landscape for GLP-1 medications has shifted decisively. In the seminal STEP 1 trial, semaglutide (Wegovy) demonstrated a mean body weight reduction of 14.9% from baseline at week 68, compared to just 2.4% with placebo, establishing a new benchmark for obesity pharmacotherapy (Wilding JP et al., NEJM, 2021) [1]. This efficacy fueled unprecedented demand, leading to prolonged shortages of both semaglutide and tirzepatide (Zepbound). These shortages, in turn, opened the door for compounded versions of these drugs. However, the FDA’s recent actions have largely closed that door. As of early 2025, both tirzepatide and semaglutide have been removed from the agency’s drug shortage list, triggering strict cessation requirements for compounded alternatives.

This article dissects the FDA’s GLP-1 compounding policy, details the shortage resolution timeline for tirzepatide and semaglutide, and explains what these regulatory shifts mean for patients currently using or considering compounded weight loss drugs. The era of widespread GLP-1 compounding is rapidly concluding.

The Foundation of Compounding: FDA’s Shortage Policy

Drug compounding serves a critical, albeit narrow, purpose: to create custom medications for individual patients with specific medical needs that cannot be met by commercially available products. This might include patients with allergies to inactive ingredients or those requiring specific dosage forms (e.g., liquid instead of pill). Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic (FD&C) Act, compounding is generally permitted only when an FDA-approved drug is on the agency’s official drug shortage list.

The rationale is clear: when an approved drug is unavailable, compounding provides an essential bridge. However, this permission ceases once the shortage is resolved and the FDA-approved product is readily accessible. Compounded drugs are not FDA-approved. They do not undergo the rigorous safety, efficacy, and quality control reviews that branded medications do. This distinction forms the bedrock of the FDA’s recent crackdown.

Tirzepatide: Shortage Ends, Compounding Ceases

Tirzepatide, approved for type 2 diabetes as Mounjaro and for weight management as Zepbound, faced significant supply constraints following its rapid adoption. The FDA officially listed Zepbound on its drug shortage database for an extended period, allowing for the legal compounding of tirzepatide.

However, in a significant development, the FDA removed tirzepatide from its drug shortage list in December 2024 [3]. This action immediately triggered a mandated wind-down period for compounding pharmacies. According to reports detailing the FDA’s directive, all compounding, distributing, or dispensing of compounded tirzepatide injections was required to end within 90 days of its removal from the shortage list [4].

This means that by March 2025, the production and distribution of compounded tirzepatide became generally impermissible. Pharmacies that continue to compound tirzepatide beyond this period are operating outside of FDA guidelines and risk enforcement action.

Semaglutide: Following Suit

Semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for weight loss, experienced similar, if not more pronounced, shortages than tirzepatide. For much of 2023 and 2024, various dosages of both Ozempic and Wegovy were consistently present on the FDA’s drug shortage database, legitimizing the compounding of semaglutide during that period.

Mirroring the action taken with tirzepatide, the FDA removed semaglutide from its drug shortage list in February 2025 [3]. This marked a pivotal moment for the compounded semaglutide market. Once a drug is no longer in shortage, the general conditions that permit compounding under Sections 503A and 503B no longer apply for the mass production of what are essentially copies of approved drugs. While a specific 90-day wind-down period similar to tirzepatide was not as widely publicized for semaglutide, the regulatory principle is the same: compounding of the product is no longer legally permissible once the approved drug is available.

The removal of both GLP-1s from the shortage list signals a clear message from the FDA: supply issues have largely been resolved, and patients should now seek FDA-approved products.

GLP-1 Shortage & Compounding Status Timeline (As of March 2026)

Why the FDA is Cracking Down: Safety and Efficacy Concerns

The FDA’s stricter stance on GLP-1 compounding is rooted in significant safety and quality concerns. The agency has issued multiple warnings regarding compounded GLP-1 drugs, highlighting several critical risks:

• Unapproved Ingredients: Many compounded GLP-1 products, particularly semaglutide, have been found to contain semaglutide salts (e.g., semaglutide sodium or acetate). These salt forms are not the active ingredient used in FDA-approved Ozempic or Wegovy. “FDA has received adverse event reports from consumers who have purchased compounded semaglutide that contained salt forms of semaglutide,” the agency stated [2]. The safety and efficacy of these salt forms are not established.
• Lack of Sterility and Quality Control: Compounded drugs are not subject to the stringent manufacturing standards of FDA-approved drugs. This can lead to issues such as non-sterile products, incorrect dosages, and the presence of impurities. The FDA’s warnings often underscore the risk of serious adverse events due to these quality failures.
• No Clinical Trials or Efficacy Data: There are no clinical trials proving the safety or effectiveness of compounded GLP-1 products. Patients taking these drugs are essentially participating in an uncontrolled experiment with unknown outcomes.
• Misleading Marketing: Many compounding pharmacies and telehealth platforms have marketed these products as “generic” versions of Ozempic or Wegovy, which is false. There are no FDA-approved generic versions of semaglutide or tirzepatide.

The FDA has actively pursued enforcement actions, including issuing warning letters to compounding pharmacies and telehealth providers found to be violating federal law by illegally marketing compounded GLP-1 drugs. These actions reinforce the agency’s commitment to ensuring patient safety and the integrity of the drug supply chain.

Key Differences: Compounded vs. FDA-Approved GLP-1s

Understanding the fundamental distinctions between compounded and FDA-approved GLP-1 medications is crucial for patient decision-making.

What This Means for Patients

For patients currently using compounded GLP-1 medications for weight loss, the regulatory shift necessitates immediate action and careful consideration.

1. Consult Your Healthcare Provider: The most crucial step is to speak with your prescribing physician about transitioning to an FDA-approved GLP-1 medication. Your doctor can assess your options, discuss potential benefits and risks, and help you navigate the process.
2. Discontinuation of Compounded Drugs: Given the FDA’s position and the safety concerns, continuing compounded versions is generally ill-advised. Your doctor will guide